ATE392893T1 - Neue behandlungsmethoden durch verwendung von phenethylaminderivaten - Google Patents

Neue behandlungsmethoden durch verwendung von phenethylaminderivaten

Info

Publication number
ATE392893T1
ATE392893T1 AT06017469T AT06017469T ATE392893T1 AT E392893 T1 ATE392893 T1 AT E392893T1 AT 06017469 T AT06017469 T AT 06017469T AT 06017469 T AT06017469 T AT 06017469T AT E392893 T1 ATE392893 T1 AT E392893T1
Authority
AT
Austria
Prior art keywords
alkyl
hydrogen
disorder
syndrome
compound
Prior art date
Application number
AT06017469T
Other languages
English (en)
Inventor
Richard Leslie Rudolph
Albert Thomas Derivan
Eric Anthony Muth
Gertrude Virginia Upton
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE392893(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE392893T1 publication Critical patent/ATE392893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT06017469T 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylaminderivaten ATE392893T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8384893A 1993-06-28 1993-06-28

Publications (1)

Publication Number Publication Date
ATE392893T1 true ATE392893T1 (de) 2008-05-15

Family

ID=22181084

Family Applications (3)

Application Number Title Priority Date Filing Date
AT94304252T ATE213407T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylderivaten
AT06017469T ATE392893T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylaminderivaten
AT01115854T ATE342715T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylderivaten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94304252T ATE213407T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylderivaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01115854T ATE342715T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylderivaten

Country Status (15)

Country Link
US (8) US5916923A (de)
EP (3) EP1738753B1 (de)
JP (2) JPH0789851A (de)
KR (1) KR100342762B1 (de)
AT (3) ATE213407T1 (de)
AU (2) AU6592994A (de)
CA (1) CA2126305C (de)
CY (1) CY2315B1 (de)
DE (3) DE69435095T2 (de)
DK (3) DK0639374T3 (de)
ES (3) ES2273764T3 (de)
HK (1) HK1038880B (de)
LV (1) LV12881B (de)
PT (3) PT1738753E (de)
SG (1) SG47711A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
ATE229328T1 (de) * 1994-02-14 2002-12-15 Wyeth Corp Venlafaxin und seine analoga zum herbeiführen einer verbesserung der kognitiven funktionen
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (de) * 1996-03-25 2015-08-26 Wyeth LLC Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
WO2000003701A1 (en) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
DE60038911D1 (de) * 1999-12-30 2008-06-26 Lundbeck & Co As H 4-Phenylpiperazinyl, -piperidinyl und -tetrahydropyridyl-Derivate als Dopamin D4-Antagonisten
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6673838B2 (en) * 2001-02-12 2004-01-06 Wyeth Succinate salt of O-desmethyl-venlafaxine
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
TW200301101A (en) * 2001-12-05 2003-07-01 Wyeth Corp Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
AR039162A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Formulaciones de venlafaxina de liberacion extendida
AU2003226748A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Compositions of venlafaxine base
AU2003226751A1 (en) 2002-03-28 2003-10-13 Synthon B.V. Low water-soluble venlafaxine salts
WO2003082804A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine besylate
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
WO2004047718A2 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004075902A1 (en) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US20060193912A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
US20060252825A1 (en) * 2005-04-22 2006-11-09 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
TW200722081A (en) * 2005-04-22 2007-06-16 Wyeth Corp New therapeutic combinations for the treatment or prevention of depression
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
AR056980A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
GT200600165A (es) * 2005-04-22 2007-03-14 Derivados dihidrobenzofuranos y usos de los mismos
CA2625832A1 (en) * 2005-10-19 2007-04-26 Vinod Kumar Kansal Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride
EP1954669B1 (de) * 2005-12-01 2015-07-08 Auspex Pharmaceuticals, Inc. Substituierte phenethylamine mit serotoninergischer und/oder norepinephrinergischer aktivität
CA2629609A1 (en) 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
JP2010507667A (ja) * 2006-10-25 2010-03-11 ワイス エルエルシー Ｏ−デスメチルベンラファキシンの単離されたヒドロキシおよびｎ−オキシド代謝産物および誘導体および治療方法
HUE031070T2 (en) * 2007-03-15 2017-06-28 Auspex Pharmaceuticals Inc Deuterated d9-venlafaxine
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
EP2222302A1 (de) * 2007-11-20 2010-09-01 NeuroSearch A/S Verfahren zur behandlung von over-eating-störungen
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
CZ200969A3 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
US9223364B2 (en) * 2012-10-25 2015-12-29 Inhon International Co., Ltd. Heat dissipation control system for portable electrical device and control method thereof
KR102132304B1 (ko) 2020-02-17 2020-07-09 박광순 접이식 유아용 비데
RU2741226C1 (ru) * 2020-09-08 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики агрессии лиц с интернет-зависимостью

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) * 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US3894051A (en) * 1973-07-05 1975-07-08 Colgate Palmolive Co N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
EP0386117B1 (de) * 1987-10-22 1999-01-07 Massachusetts Institute Of Technology Behandlung des prämenstruellen oder späten lutealsphase-syndroms
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
FI910897A (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
ZA912277B (en) * 1990-03-29 1992-11-25 Lilly Co Eli The selective occupation of serotonin ic receptors
JPH07500812A (ja) * 1991-11-15 1995-01-26 セプラコア，インコーポレーテッド 純粋なフルオキセチンのｓ（＋）異性体を用いる方法および組成物
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives

Also Published As

Publication number Publication date
EP1738753A3 (de) 2007-01-31
DE69429895D1 (de) 2002-03-28
DE69429895T2 (de) 2002-08-29
AU5831298A (en) 1998-05-21
CA2126305C (en) 2006-10-17
DK1153603T3 (da) 2006-12-18
EP0639374A3 (de) 1995-08-02
ES2304041T3 (es) 2008-09-01
ATE213407T1 (de) 2002-03-15
US6555586B2 (en) 2003-04-29
EP1153603A2 (de) 2001-11-14
PT1153603E (pt) 2007-01-31
KR100342762B1 (ko) 2002-11-18
JPH0789851A (ja) 1995-04-04
US20040110829A1 (en) 2004-06-10
SG47711A1 (en) 1998-04-17
ATE342715T1 (de) 2006-11-15
DE69434872T2 (de) 2007-04-05
US6444708B2 (en) 2002-09-03
EP1738753A2 (de) 2007-01-03
DE69435095T2 (de) 2009-07-02
US20020052405A1 (en) 2002-05-02
HK1038880B (zh) 2006-12-22
EP0639374A2 (de) 1995-02-22
US6465524B2 (en) 2002-10-15
LV12881B (en) 2002-11-20
US20030181517A1 (en) 2003-09-25
DK0639374T3 (da) 2002-05-06
DK1738753T3 (da) 2008-08-11
AU6592994A (en) 1995-01-05
JP2006117689A (ja) 2006-05-11
US20010053799A1 (en) 2001-12-20
EP1153603B1 (de) 2006-10-18
PT639374E (pt) 2002-07-31
DE69435095D1 (de) 2008-06-05
EP1153603A3 (de) 2003-05-21
DE69434872D1 (de) 2006-11-30
ES2273764T3 (es) 2007-05-16
US5916923A (en) 1999-06-29
KR950000139A (ko) 1995-01-03
ES2174864T3 (es) 2002-11-16
US20010012855A1 (en) 2001-08-09
HK1038880A1 (en) 2002-04-04
US6310101B1 (en) 2001-10-30
EP1738753B1 (de) 2008-04-23
CY2315B1 (en) 2003-11-14
US20080176950A1 (en) 2008-07-24
EP0639374B1 (de) 2002-02-20
CA2126305A1 (en) 1994-12-29
US6730706B2 (en) 2004-05-04
PT1738753E (pt) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE392893T1 (de) Neue behandlungsmethoden durch verwendung von phenethylaminderivaten
NO942415L (no) Fremgangsmåte for fremstilling av behandling av surgass og hydrokarbonvæskeströmmer
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
DK0582790T3 (da) Ny fremgangsmåde til fremstilling af 7-substituerede-9-[(substitueret glycyl)-amino]-6-demethyl-6-deoxytetracycliner
BR9502390A (pt) Ligaçoes 1 fenil-3-dimetilamino-propano processo para a preparaçao de ligaçoes 1-fenil-3-dimetilamino-propano substância ativa farmacêutica e analgésica
BR0310083A (pt) Métodos de tratar distúrbios de dor gastrointestinal e genitourinária empregando-se venlafaxina e derivados
ES2037779T3 (es) Procedimiento para preparar nuevos compuestos de amida.
HU9601217D0 (en) Antracyclinone derivatives and their use for treating amyloidosis
GB8804443D0 (en) Compounds
ATE413378T1 (de) Verfahren zur herstellung von phenylethylaminen, insbesondere venlafaxin
PL341281A1 (en) Novel acronicin compounds, method of obtaining them and pharmacological compoistions containing such compounds
FI860074A (fi) Oktahydroindolizinfoereningar anvaendbara som smaertstillande medel.
NO870423D0 (no) 5-substituert octahydroindolizin-analgetika-forbindelser og 7-keto-mellomprodukt.
PT82527B (pt) Processo para a preparacao de derivados de hidroxi-ciclo-alquil-fenoxi-etilamina
DK0667150T3 (da) Venlafaxin og dens analoger til fremkaldelse af en forbedring af de kognitive funktioner
WO1989008098A3 (en) Lipophilic polyamines useful for treating hypercholesterolemia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1738753

Country of ref document: EP

RZN Patent revoked